Darou Darman Arang is a fast growing pharmaceutical Company in Iran.
Darou Darman Arang is a fast growing pharmaceutical Company in Iran.
We are a fast growing pharmaceutical company manufacturing our own brands and representing pharmaceutical companies from around the world in Iran to import medicines.
DAROU DARMAN ARANG acts as the representative agent for specialty, rare disease, biotech and vaccine producing companies looking to penetrate to Iran. We are the preferred strategic partner, providing turn-key solutions and support for their commercial operations…… Read more
We have ensured world-class quality in design, equipment and operations in our manufacturing facility. Our units ensure that we are able to provide best-in-class products to patients across the Iran and emerging markets around. Our manufacturing operations are focused on producing generics and branded generics, in the full range of dosage forms, including tablets, capsules, injectable, pre-filled syringe and freeze dried powder. …… Read more
Imports of Finished Pharmaceuticals
As the pioneer of our mission to meet the needs of the health society across IRAN and beyond with our expert staffs and facilities to import different health care products…… Read more
We in R&D department aimed to Reach to various market requirements and high quality products, by representing formulation and providing new method analysis, taking advantage of experienced Experts, using the most up to dated sources of pharmaceuticals and advanced devices. In addition to exploitation of cooperation and consultation of prominent University professors and other authentic science centers.
Read MoreRegulatory
Having sufficient knowledge of drug registration rules & regulations for registration of products
Adequately capability of registering new products in the Drug National List
Well knowledge of the drug, raw material and food supplement approval process and registration bureaucracy in Ministry of Health
Submitting registration documents to MOH
DAROU DARMAN ARANG COMPANY WAS ESTABLISHED BY A GROUP OF EXPERIENCED PEOPLE TO ATTRACT, DEVELOP AND DELIVER NEW CAPABILITIES.
<p>The European Medicines Agency (EMA) has formally adopted a landmark reflection paper that is set to streamline the development and approval of biosimilar medicines, potentially reducing the need for extensive and costly clinical efficacy studies.</p>
<p>On 26 February 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions positive opinions, recommending the granting of a marketing authorization for two biosimilar medicines: Henlius’ Poherdy (pertuzumab) and Gedeon Richter’s Tuyory (tocilizumab). Additionally, Henlius marks the first anniversary of the European Commission’s (EC) approval of its novel biological, Hetronifly (serplulimab).</p>
<p>US President Donald J Trump launched the ‘TrumpRx’ website in February 2026. It is designed to connectAmericans directly with manufacturers and enable access to lower-priced prescription drugs.</p>
